Autolus

Cell and Gene
Share

Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.